Merck Signs MoU with Lotte Biologics for Biologics Manufacturing

• Merck named preferred supplier for Lotte’s new biologics business
• Companies to collaborate on facility design, workforce training on process development and testing
• Merck to supply manufacturing hardware and consumables and technical support

Burlington, MA, June 29, 2022 – Merck, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, signed a non-binding Memorandum of Understanding (MoU) with the new biologics business of Lotte Group, outlining a planned collaboration to establish Lotte’s biologics manufacturing capabilities in the USA. The MoU contemplates that Merck will be a preferred supplier to provide Lotte with technical consulting, training and expertise, products, technologies, and manufacturing solutions.

“Novel modalities are changing the landscape of medicine and are expected to rapidly expand in the coming years to support development of customized, next-generation therapies, drugs, and vaccines,” said Andrew Bulpin, head of Process Solutions, Life Science, at Merck KGaA, Darmstadt, Germany. “This collaboration is just one example of our ongoing commitment to impact life and health with science.”

The Life Science business of Merck KGaA, Darmstadt, Germany has well over 30 years’ experience in process development and GMP manufacturing. The company has helped bring more than 280 biologics to market and has released more than 100 GMP drug substances since 2012 across a range of molecules and scales.

“We are delighted to announce our collaboration with Merck. We believe such a relationship is a perfect fit for our mutual growth and business value and we look forward to strengthening and fostering this partnership not only in the U.S. but further on a global level to place both parties on the best path for consistent success,” said Richard Lee, CEO of Lotte Biologics.